Vaping Discontinuation Assistance
For adults seeking to quit vaping, combine varenicline (1 mg twice daily for 12 weeks) with behavioral counseling as first-line therapy, as this combination demonstrates the strongest evidence for sustained abstinence.
Pharmacotherapy Recommendations
Varenicline (First-Line)
- Varenicline is the most effective pharmacotherapy for vaping cessation, doubling quit rates compared to placebo (40% vs 20% continuous abstinence at weeks 4-12) 1
- Dosing: 1 mg twice daily for 12 weeks
- Evidence shows sustained benefit through 24 weeks (34.3% vs 17.2% continuous abstinence) 1
- Low-certainty evidence from pooled analyses confirms benefit (RR 2.00,95% CI 1.09-3.68) 2
- Safety profile: Serious adverse events were infrequent and not treatment-related 1
Nicotine Replacement Therapy (Alternative Option)
- NRT may help people quit vaping, though evidence is less robust than for varenicline 2
- Combination NRT (patch plus fast-acting form) is preferred based on smoking cessation data showing superiority over single-form NRT (RR 1.25) 3
- Current vaping cessation data for NRT shows very low certainty due to imprecision 2
Bupropion (Not Recommended)
- Insufficient evidence to support bupropion for vaping cessation 2
Behavioral Interventions
Text Message-Based Programs (Evidence-Based for Youth/Young Adults)
- Low-certainty evidence suggests text message interventions increase quit rates in 13-24 year-olds (RR 1.32,95% CI 1.19-1.47) 2
- Particularly useful for adolescent and young adult populations
- Can be combined with pharmacotherapy for enhanced effect
Counseling Support
- Behavioral counseling combined with pharmacotherapy shows additive benefit based on smoking cessation literature 3
- At least 4 counseling sessions recommended, with total contact time of 90-300 minutes 3
- Can be delivered by non-specialists without loss of effectiveness 3
- Telephone and asynchronous messaging support combined with cognitive behavioral therapy shows feasibility 4
Practical Implementation Algorithm
Step 1: Assess readiness and select intervention
- For motivated adults: Varenicline + counseling
- For youth/young adults (13-24 years): Text message program ± varenicline (if age-appropriate)
- For those declining varenicline: Combination NRT + counseling
Step 2: Initiate pharmacotherapy
- Varenicline: Standard 12-week course (1 mg BID)
- NRT: Patch plus fast-acting form (gum, lozenge, or inhaler)
Step 3: Provide behavioral support
- Minimum 4 counseling sessions over treatment period
- Include relapse prevention strategies
- Consider digital/text message adjuncts for younger users
Step 4: Monitor and adjust
- Follow through 24 weeks minimum
- Address dual use concerns (concurrent tobacco smoking)
- Monitor for adverse events, though serious events are rare
Critical Caveats
Dual Use Considerations: Most studies included participants who were abstinent from combustible tobacco at baseline 2. For those using both products, prioritize complete tobacco abstinence while addressing vaping cessation.
Evidence Limitations: The vaping cessation evidence base is substantially weaker than for smoking cessation 2, 5. However, extrapolation from smoking cessation data supports similar pharmacotherapy approaches 3.
Pregnancy and Special Populations: No high-quality data exists for vaping cessation in pregnancy. Behavioral interventions should be prioritized, with pharmacotherapy decisions made cautiously 6.
Harm Reduction vs. Abstinence: While some advocate gradual nicotine reduction, evidence for this approach is very low certainty 2. Complete abstinence remains the primary goal.